NeuroPace, Inc.
NPCE Healthcare Medical Devices
In the quarter to June 2026, revenue grew 17.1%, EPS grew 30.8%, free cash flow fell 78.7% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow NPCE
NeuroPace, Inc. (NPCE) EV/Sales
As of 16 October 2026, NeuroPace, Inc. (NPCE) trades at a EV/Sales of 4.2×. Over the past ten years it has ranged from 0.0× (December 2022) to 7.7× (November 2021); the current reading is higher than 60% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.1× | 20.40% |
| FY2024 | 4.2× | 11.50% |
| FY2023 | 3.8× | 1,083.94% |
| FY2022 | 0.3× | (86.32%) |
| FY2021 | 2.3× | 236.59% |
| FY2020 | 0.7× | 0.00% |
| FY2019 | 0.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 5.4× | 18.35% |
| Mar 2026 | 4.5× | (10.38%) |
| Dec 2025 | 5.1× | 33.84% |
| Sep 2025 | 3.8× | (12.58%) |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OFIX ORTHOFIX MEDICAL INC. compare | 0.6× |
| CERS Cerus Corporation compare | 1.8× |
| BWAY Brainsway Ltd. Sponsored ADR compare | 2.6× |
| NPCE NeuroPace, Inc. | 4.2× |
| DCTH Delcath Systems, Inc. compare | 4.3× |
| SI Shoulder Innovations, Inc. compare | 4.8× |
| SGHT Sight Sciences, Inc. compare | 4.9× |
| MASS 908 Devices Inc. compare | 5.6× |
| SENS Senseonics Holdings, Inc. compare | 8.1× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)